 DUBLIN, Jan. 18, 2022 PRNewswire -- Alkermes plc Nasdaq: ALKS today announced plans to present a poster related to nemvaleukin alfa nemvaleukin, the companys novel, investigational, engineered interleukin-2 IL-2 variant immunotherapy, at the American Society of Clinical Oncology ASCO Gastrointestinal GI Cancers Symposium, taking place Jan. 20-22, 2022. The poster highlights clinical data related to advanced GI cancers from ARTISTRY-1, a phase 12 study evaluating the tolerability and efficacy of nemvaleukin administered intravenously as a monotherapy and in combination with pembrolizumab KEYTRUDA, and preclinical data from the study of nemvaleukin in combination with novel agents in GI cancers. 